RU2006134000A - Новые кетоамиды с циклическим p4s, действующие как ингибиторы сериновой протеазы ns3 ируса гепатита с - Google Patents
Новые кетоамиды с циклическим p4s, действующие как ингибиторы сериновой протеазы ns3 ируса гепатита с Download PDFInfo
- Publication number
- RU2006134000A RU2006134000A RU2006134000/04A RU2006134000A RU2006134000A RU 2006134000 A RU2006134000 A RU 2006134000A RU 2006134000/04 A RU2006134000/04 A RU 2006134000/04A RU 2006134000 A RU2006134000 A RU 2006134000A RU 2006134000 A RU2006134000 A RU 2006134000A
- Authority
- RU
- Russia
- Prior art keywords
- compound
- group
- alkyl
- heterocyclyl
- pharmaceutical composition
- Prior art date
Links
- 0 *CC1NCC1 Chemical compound *CC1NCC1 0.000 description 42
- JHCRGWVAEYIVAN-UHFFFAOYSA-N CC(C)(C)N(CCN1C[IH]C)S1(=O)=O Chemical compound CC(C)(C)N(CCN1C[IH]C)S1(=O)=O JHCRGWVAEYIVAN-UHFFFAOYSA-N 0.000 description 1
- PBZHTQZXXTXWTK-QXXIUIOUSA-N CC(C)(CC1C2)[C@@H]1[C@@H](C(C)=O)N2C(C)=O Chemical compound CC(C)(CC1C2)[C@@H]1[C@@H](C(C)=O)N2C(C)=O PBZHTQZXXTXWTK-QXXIUIOUSA-N 0.000 description 1
- IDKAJTIEEAKXAB-VIFPVBQESA-N CC(C)(C[C@H]1C(C)=O)CN1C(C)=O Chemical compound CC(C)(C[C@H]1C(C)=O)CN1C(C)=O IDKAJTIEEAKXAB-VIFPVBQESA-N 0.000 description 1
- NLOOSIQADIMKFF-AEJSXWLSSA-N CC(C)(O[C@H]1C2)O[C@@H]1[C@@H](C(C)=O)N2C(C)=O Chemical compound CC(C)(O[C@H]1C2)O[C@@H]1[C@@H](C(C)=O)N2C(C)=O NLOOSIQADIMKFF-AEJSXWLSSA-N 0.000 description 1
- BYKYPYPHULOVEW-UHFFFAOYSA-N CC(C)C(CC1)CCC1(F)F Chemical compound CC(C)C(CC1)CCC1(F)F BYKYPYPHULOVEW-UHFFFAOYSA-N 0.000 description 1
- XPCKQTDUEAQGTK-UWYWSCPESA-N CC(C)C(CC1)[C@@H](C(NC(CCC#C)C(C(NCC=C)=O)=O)=O)N1C([C@H](C(C)(C)C)NC(NC(CN(C(CC(C)(C)C1)=O)C1=O)C(C)(C)C)=O)=O Chemical compound CC(C)C(CC1)[C@@H](C(NC(CCC#C)C(C(NCC=C)=O)=O)=O)N1C([C@H](C(C)(C)C)NC(NC(CN(C(CC(C)(C)C1)=O)C1=O)C(C)(C)C)=O)=O XPCKQTDUEAQGTK-UWYWSCPESA-N 0.000 description 1
- FKHKVNXFZNSTGO-YYDDNLMPSA-N CC(C)C(CC1)[C@@H](C(NC(CCC#C)C(C(NCC=C)=O)=O)=O)N1C([C@H](C1CCCCC1)NC(N[C@H](CN(CCCN1C)S1(=O)=O)C(C)(C)C)=O)=O Chemical compound CC(C)C(CC1)[C@@H](C(NC(CCC#C)C(C(NCC=C)=O)=O)=O)N1C([C@H](C1CCCCC1)NC(N[C@H](CN(CCCN1C)S1(=O)=O)C(C)(C)C)=O)=O FKHKVNXFZNSTGO-YYDDNLMPSA-N 0.000 description 1
- UPJQYODQOCCRRR-HCIQBXGHSA-N CC(C)C(C[C@H]1C(NC(CC2CC2)C(C(N)=O)=O)=O)CN1C([C@H](C(C)(C)C)NC(N[C@H](CN(Cc1ccccc11)S1(=O)=O)C(C)(C)C)=O)=O Chemical compound CC(C)C(C[C@H]1C(NC(CC2CC2)C(C(N)=O)=O)=O)CN1C([C@H](C(C)(C)C)NC(N[C@H](CN(Cc1ccccc11)S1(=O)=O)C(C)(C)C)=O)=O UPJQYODQOCCRRR-HCIQBXGHSA-N 0.000 description 1
- RZWOTQFLJRNXJA-FBGLDOHJSA-N CC(C)C(C[C@H]1C(NC(CC2CCC2)C(C(N)=O)=O)=O)CN1C([C@H](C(C)(C)C)NC(N[C@H](CN(Cc1ccccc11)S1(=O)=O)C(C)(C)C)=O)=O Chemical compound CC(C)C(C[C@H]1C(NC(CC2CCC2)C(C(N)=O)=O)=O)CN1C([C@H](C(C)(C)C)NC(N[C@H](CN(Cc1ccccc11)S1(=O)=O)C(C)(C)C)=O)=O RZWOTQFLJRNXJA-FBGLDOHJSA-N 0.000 description 1
- DZICCLVVNVURFW-UHFFFAOYSA-N CC(C)C1(C)CCOCC1 Chemical compound CC(C)C1(C)CCOCC1 DZICCLVVNVURFW-UHFFFAOYSA-N 0.000 description 1
- IOOXDDQLNSTLNL-UHFFFAOYSA-N CC(C)CN(CCCC1)C1=O Chemical compound CC(C)CN(CCCC1)C1=O IOOXDDQLNSTLNL-UHFFFAOYSA-N 0.000 description 1
- JNVUDATVGQZFOI-UHFFFAOYSA-N CC(C)CN(CCCN1)C1=O Chemical compound CC(C)CN(CCCN1)C1=O JNVUDATVGQZFOI-UHFFFAOYSA-N 0.000 description 1
- MOQYJGPXVIAPOT-UHFFFAOYSA-N CC(C)CN(Cc1ccccc11)S1(=O)=O Chemical compound CC(C)CN(Cc1ccccc11)S1(=O)=O MOQYJGPXVIAPOT-UHFFFAOYSA-N 0.000 description 1
- JKHCHASMRXRYGE-UHFFFAOYSA-N CC(C)CN1SCCCC1=O Chemical compound CC(C)CN1SCCCC1=O JKHCHASMRXRYGE-UHFFFAOYSA-N 0.000 description 1
- XEVXLJNFZXAVSC-IPBGHOEGSA-N CC(C)[C@@H](CN(CCC1)S1(=O)=O)NC(N[C@@H](C(C)(C)C)C(N(CC(C1)C(C)C)[C@@H]1C(NC(CC1CC1)C(C(NC)=O)=O)=O)=O)=O Chemical compound CC(C)[C@@H](CN(CCC1)S1(=O)=O)NC(N[C@@H](C(C)(C)C)C(N(CC(C1)C(C)C)[C@@H]1C(NC(CC1CC1)C(C(NC)=O)=O)=O)=O)=O XEVXLJNFZXAVSC-IPBGHOEGSA-N 0.000 description 1
- VIEKEHJFNWZURG-VEBXRMAPSA-N CC(C)[C@H](C[C@H]1C(NC(CC2CCC2)C(C(N)=O)=O)=O)CN1C([C@H](C(C)(C)C)NC(N[C@H](CN(CCN1)S1(=O)=O)C(C)(C)C)=O)=O Chemical compound CC(C)[C@H](C[C@H]1C(NC(CC2CCC2)C(C(N)=O)=O)=O)CN1C([C@H](C(C)(C)C)NC(N[C@H](CN(CCN1)S1(=O)=O)C(C)(C)C)=O)=O VIEKEHJFNWZURG-VEBXRMAPSA-N 0.000 description 1
- YDVYHEXBRNKDJG-HSOSERFQSA-N CC(C[C@H]1C(C)=O)CN1C(C)=O Chemical compound CC(C[C@H]1C(C)=O)CN1C(C)=O YDVYHEXBRNKDJG-HSOSERFQSA-N 0.000 description 1
- HPRITURHSXTUDO-JGVFFNPUSA-N CC([C@H]([C@H](CC1)C(Cl)Cl)N1C(C)=O)=O Chemical compound CC([C@H]([C@H](CC1)C(Cl)Cl)N1C(C)=O)=O HPRITURHSXTUDO-JGVFFNPUSA-N 0.000 description 1
- KFGFSYAJELATDC-BIIVOSGPSA-N CC([C@H]([C@H]([C@@H]1C2)C1(Cl)Cl)N2C(C)=O)=O Chemical compound CC([C@H]([C@H]([C@@H]1C2)C1(Cl)Cl)N2C(C)=O)=O KFGFSYAJELATDC-BIIVOSGPSA-N 0.000 description 1
- ZOLOOMHRCHIDJK-BIIVOSGPSA-N CC([C@H]([C@H]([C@@H]1C2)C1(F)F)N2C(C)=O)=O Chemical compound CC([C@H]([C@H]([C@@H]1C2)C1(F)F)N2C(C)=O)=O ZOLOOMHRCHIDJK-BIIVOSGPSA-N 0.000 description 1
- MHHRVAYBKLATSY-HCIQBXGHSA-N CCCCC(C(C(N)=O)=O)NC([C@H](CC(C1)C(C)C)N1C([C@H](C(C)(C)C)NC(N[C@H](CN(Cc1ccccc11)S1(=O)=O)C(C)(C)C)=O)=O)=O Chemical compound CCCCC(C(C(N)=O)=O)NC([C@H](CC(C1)C(C)C)N1C([C@H](C(C)(C)C)NC(N[C@H](CN(Cc1ccccc11)S1(=O)=O)C(C)(C)C)=O)=O)=O MHHRVAYBKLATSY-HCIQBXGHSA-N 0.000 description 1
- UXSITJBDGCVNCB-VJBGASIXSA-N CCCCC(C(C(NCC)=O)=O)NC([C@H](C[C@H](C1)C(C)C)N1C([C@H](C1CCCCC1)NC(NC(CC(C)(C)C)CN(CCC1)S1(=O)=O)=O)=O)=O Chemical compound CCCCC(C(C(NCC)=O)=O)NC([C@H](C[C@H](C1)C(C)C)N1C([C@H](C1CCCCC1)NC(NC(CC(C)(C)C)CN(CCC1)S1(=O)=O)=O)=O)=O UXSITJBDGCVNCB-VJBGASIXSA-N 0.000 description 1
- KDTYAJFCKAXXNQ-DUECVZMVSA-N CCCCC(C(C(NCC=C)=O)=O)NC([C@H](C(C1C2)C1(Cl)Cl)N2C([C@H](C(C)(C)C)NC(N[C@H](CN(C(c1c2cccc1)=O)C2=O)C(C)(C)C)=O)=O)=O Chemical compound CCCCC(C(C(NCC=C)=O)=O)NC([C@H](C(C1C2)C1(Cl)Cl)N2C([C@H](C(C)(C)C)NC(N[C@H](CN(C(c1c2cccc1)=O)C2=O)C(C)(C)C)=O)=O)=O KDTYAJFCKAXXNQ-DUECVZMVSA-N 0.000 description 1
- LKCCLYGBSKWNTR-OKLZREHDSA-N CCCCC(C(C(NCC=C)=O)=O)NC([C@H](C(CC1)C(C)C)N1C([C@H](C1CCCCC1)NC(NC(CN(C(CCC1(C)C)=O)C1=O)C(C)(C)C)=O)=O)=O Chemical compound CCCCC(C(C(NCC=C)=O)=O)NC([C@H](C(CC1)C(C)C)N1C([C@H](C1CCCCC1)NC(NC(CN(C(CCC1(C)C)=O)C1=O)C(C)(C)C)=O)=O)=O LKCCLYGBSKWNTR-OKLZREHDSA-N 0.000 description 1
- PJPZFHYMCATOJL-UHFFFAOYSA-N CCCN(C(CCN1C)=O)C1=O Chemical compound CCCN(C(CCN1C)=O)C1=O PJPZFHYMCATOJL-UHFFFAOYSA-N 0.000 description 1
- BELGHMWMXFCZTP-UHFFFAOYSA-N CCN(CCO1)C1=O Chemical compound CCN(CCO1)C1=O BELGHMWMXFCZTP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/706—Specific hybridization probes for hepatitis
- C12Q1/707—Specific hybridization probes for hepatitis non-A, non-B Hepatitis, excluding hepatitis D
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54850604P | 2004-02-27 | 2004-02-27 | |
| US60/548,506 | 2004-02-27 | ||
| PCT/US2005/005924 WO2005085242A1 (en) | 2004-02-27 | 2005-02-24 | Novel ketoamides with cyclic p4's as inhibitors of ns3 serine protease of hepatitis c virus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2006134000A true RU2006134000A (ru) | 2008-04-10 |
Family
ID=34919371
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2006134000/04A RU2006134000A (ru) | 2004-02-27 | 2005-02-24 | Новые кетоамиды с циклическим p4s, действующие как ингибиторы сериновой протеазы ns3 ируса гепатита с |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US7173057B2 (enExample) |
| EP (1) | EP1730142B1 (enExample) |
| JP (1) | JP4874227B2 (enExample) |
| KR (1) | KR20070026394A (enExample) |
| CN (1) | CN1946718A (enExample) |
| AR (1) | AR048023A1 (enExample) |
| AT (1) | ATE514691T1 (enExample) |
| AU (1) | AU2005219824B2 (enExample) |
| BR (1) | BRPI0508217A (enExample) |
| CA (1) | CA2557304C (enExample) |
| EC (1) | ECSP066792A (enExample) |
| IL (1) | IL177628A0 (enExample) |
| NO (1) | NO20064355L (enExample) |
| PE (1) | PE20050999A1 (enExample) |
| RU (1) | RU2006134000A (enExample) |
| TW (1) | TW200529822A (enExample) |
| WO (1) | WO2005085242A1 (enExample) |
| ZA (1) | ZA200607048B (enExample) |
Families Citing this family (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69709671T2 (de) | 1996-10-18 | 2002-08-22 | Vertex Pharmaceuticals Inc., Cambridge | Inhibitoren von serinproteasen, insbesondere von ns3-protease des hepatitis-c-virus |
| US7491794B2 (en) * | 2003-10-14 | 2009-02-17 | Intermune, Inc. | Macrocyclic compounds as inhibitors of viral replication |
| US10086511B2 (en) | 2003-11-10 | 2018-10-02 | Brooks Automation, Inc. | Semiconductor manufacturing systems |
| US8696298B2 (en) * | 2003-11-10 | 2014-04-15 | Brooks Automation, Inc. | Semiconductor manufacturing process modules |
| WO2005087721A2 (en) * | 2004-02-27 | 2005-09-22 | Schering Corporation | Compounds as inhibitors of hepatitis c virus ns3 serine protease |
| US7635694B2 (en) * | 2004-02-27 | 2009-12-22 | Schering Corporation | Cyclobutenedione-containing compounds as inhibitors of hepatitis C virus NS3 serine protease |
| US20060276407A1 (en) * | 2005-06-02 | 2006-12-07 | Schering Corporation | Methods of treating hepatitis C virus |
| AU2006252553B2 (en) * | 2005-06-02 | 2012-03-29 | Merck Sharp & Dohme Corp. | Combination of HCV protease inhibitors with a surfactant |
| CA2611145A1 (en) * | 2005-06-02 | 2006-12-07 | Schering Corporation | Controlled-release formulation useful for treating disorders associated with hepatitis c virus |
| WO2006130626A2 (en) * | 2005-06-02 | 2006-12-07 | Schering Corporation | Method for modulating activity of hcv protease through use of a novel hcv protease inhibitor to reduce duration of treatment period |
| WO2006130666A2 (en) * | 2005-06-02 | 2006-12-07 | Schering Corporation | Medicaments and methods combining a hcv protease inhibitor and an akr competitor |
| US20060275366A1 (en) * | 2005-06-02 | 2006-12-07 | Schering Corporation | Controlled-release formulation |
| WO2006130552A2 (en) * | 2005-06-02 | 2006-12-07 | Schering Corporation | Methods of treating hepatitis c virus |
| US20070021351A1 (en) * | 2005-06-02 | 2007-01-25 | Schering Corporation | Liver/plasma concentration ratio for dosing hepatitis C virus protease inhibitor |
| US20070237818A1 (en) * | 2005-06-02 | 2007-10-11 | Malcolm Bruce A | Controlled-release formulation of HCV protease inhibitor and methods using the same |
| WO2006130686A2 (en) | 2005-06-02 | 2006-12-07 | Schering Corporation | Hcv protease inhibitors in combination with food |
| NZ565059A (en) * | 2005-07-25 | 2011-08-26 | Intermune Inc | Novel macrocyclic inhibitors of hepatitus C virus replication |
| AR055395A1 (es) | 2005-08-26 | 2007-08-22 | Vertex Pharma | Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c |
| BRPI0617274A2 (pt) | 2005-10-11 | 2011-07-19 | Intermune Inc | compostos e métodos para a inibição de replicação viral de hepatite c |
| EP2392589A3 (en) | 2005-11-11 | 2012-06-20 | Vertex Pharmaceuticals Incorporated | Hepatitis C virus variants |
| US7705138B2 (en) * | 2005-11-11 | 2010-04-27 | Vertex Pharmaceuticals Incorporated | Hepatitis C virus variants |
| US7816348B2 (en) | 2006-02-03 | 2010-10-19 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
| US20070265281A1 (en) * | 2006-04-11 | 2007-11-15 | Sylvain Cottens | Organic Compounds and Their Uses |
| EP2007789B1 (en) | 2006-04-11 | 2015-05-20 | Novartis AG | Spirocyclic HCV/HIV inhibitors and their uses |
| US20080045530A1 (en) * | 2006-04-11 | 2008-02-21 | Trixi Brandl | Organic Compounds and Their Uses |
| RU2008152171A (ru) * | 2006-07-05 | 2010-08-10 | Интермьюн, Инк. (Us) | Новые ингибиторы вирусной репликации гепатита с |
| WO2008019477A1 (en) | 2006-08-17 | 2008-02-21 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
| EP2428204A3 (en) | 2006-12-07 | 2012-07-04 | Schering Corporation | pH sensitive matrix formulation |
| US20080219810A1 (en) * | 2007-03-05 | 2008-09-11 | Van Der Meulen Peter | Semiconductor manufacturing process modules |
| MX2009010205A (es) * | 2007-03-23 | 2009-10-19 | Schering Corp | Inhibidores de cetoamida p1-no epimerizables de proteasa ns3 de virus de hepatitis c. |
| WO2008118332A2 (en) * | 2007-03-23 | 2008-10-02 | Schering Corporation | Hydrazido-peptides as inhibitors of hcv ns3-protease |
| AP2009005053A0 (en) * | 2007-05-03 | 2009-12-31 | Intermune Inc | Novel macrocyclic inhibitors of hepatitis c virus replication |
| AU2008251425A1 (en) * | 2007-05-10 | 2008-11-20 | Array Biopharma, Inc. | Novel peptide inhibitors of hepatitis C virus replication |
| EP2188274A4 (en) | 2007-08-03 | 2011-05-25 | Boehringer Ingelheim Int | VIRAL POLYMERASE HEMMER |
| AU2008309589B2 (en) * | 2007-10-10 | 2012-07-05 | Novartis Ag | Spiropyrrolidines and their use against HCV and HIV infection |
| US8419332B2 (en) * | 2007-10-19 | 2013-04-16 | Atlas Bolt & Screw Company Llc | Non-dimpling fastener |
| AU2008338273B2 (en) | 2007-12-19 | 2014-10-02 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
| US8003659B2 (en) * | 2008-02-04 | 2011-08-23 | Indenix Pharmaceuticals, Inc. | Macrocyclic serine protease inhibitors |
| CA2720729A1 (en) * | 2008-04-15 | 2009-11-26 | Intermune, Inc. | Novel macrocyclic inhibitors of hepatitis c virus replication |
| CA2750227A1 (en) | 2009-01-07 | 2010-07-15 | Scynexis, Inc. | Cyclosporine derivative for use in the treatment of hcv and hiv infection |
| US8102720B2 (en) * | 2009-02-02 | 2012-01-24 | Qualcomm Incorporated | System and method of pulse generation |
| AR075584A1 (es) | 2009-02-27 | 2011-04-20 | Intermune Inc | COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO. |
| EP2403860B1 (en) | 2009-03-04 | 2015-11-04 | IDENIX Pharmaceuticals, Inc. | Phosphothiophene and phosphothiazole as hcv polymerase inhibitors |
| WO2010118078A1 (en) | 2009-04-08 | 2010-10-14 | Idenix Pharmaceuticals, Inc. | Macrocyclic serine protease inhibitors |
| US8512690B2 (en) | 2009-04-10 | 2013-08-20 | Novartis Ag | Derivatised proline containing peptide compounds as protease inhibitors |
| US20110182850A1 (en) * | 2009-04-10 | 2011-07-28 | Trixi Brandl | Organic compounds and their uses |
| CA2763140A1 (en) | 2009-05-29 | 2010-12-02 | Schering Corporation | Antiviral compounds composed of three linked aryl moieties to treat diseases such as hepatitis c |
| WO2011017389A1 (en) | 2009-08-05 | 2011-02-10 | Idenix Pharmaceuticals, Inc. | Macrocyclic serine protease inhibitors useful against viral infections, particularly hcv |
| WO2011063076A1 (en) | 2009-11-19 | 2011-05-26 | Itherx Pharmaceuticals, Inc. | Methods of treating hepatitis c virus with oxoacetamide compounds |
| EP2503881B1 (en) | 2009-11-25 | 2015-05-13 | Merck Sharp & Dohme Corp. | Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases |
| RU2554087C2 (ru) | 2009-12-18 | 2015-06-27 | Айденикс Фармасьютикалз, Инк. | 5,5-конденсированные ариленовые или гетероариленовые ингибиторы вируса гепатита с |
| JP2013515068A (ja) | 2009-12-22 | 2013-05-02 | メルク・シャープ・アンド・ドーム・コーポレーション | ウイルス性疾患の治療のための縮合三環式化合物およびその使用方法 |
| CN102918049A (zh) | 2010-03-09 | 2013-02-06 | 默沙东公司 | 稠合三环甲硅烷基化合物及其用于治疗病毒性疾病的方法 |
| AU2011286276A1 (en) | 2010-07-26 | 2013-01-24 | Merck Sharp & Dohme Corp. | Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases |
| CA2812779A1 (en) | 2010-09-29 | 2012-04-19 | Merck Sharp & Dohme Corp. | Fused tetracycle derivatives and methods of use thereof for the treatment of viral diseases |
| JP5565320B2 (ja) * | 2011-01-06 | 2014-08-06 | 富士通株式会社 | 情報処理装置及び情報処理プログラム |
| US9353100B2 (en) | 2011-02-10 | 2016-05-31 | Idenix Pharmaceuticals Llc | Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections |
| US20120252721A1 (en) | 2011-03-31 | 2012-10-04 | Idenix Pharmaceuticals, Inc. | Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor |
| PH12013502141A1 (en) | 2011-04-13 | 2014-01-06 | Merck Sharp & Dohme | 2'-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
| EP2697242B1 (en) | 2011-04-13 | 2018-10-03 | Merck Sharp & Dohme Corp. | 2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
| CN103687489A (zh) | 2011-05-18 | 2014-03-26 | 埃南塔制药公司 | 制备5-氮杂螺[2.4]庚烷-6-甲酸及其衍生物的方法 |
| WO2013033899A1 (en) | 2011-09-08 | 2013-03-14 | Merck Sharp & Dohme Corp. | Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases |
| WO2013033901A1 (en) | 2011-09-08 | 2013-03-14 | Merck Sharp & Dohme Corp. | Heterocyclic-substituted benzofuran derivatives and methods of use thereof for the treatment of viral diseases |
| WO2013033900A1 (en) | 2011-09-08 | 2013-03-14 | Merck Sharp & Dohme Corp. | Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases |
| WO2013039876A1 (en) | 2011-09-14 | 2013-03-21 | Merck Sharp & Dohme Corp. | Silyl-containing heterocyclic compounds and methods of use thereof for the treatment of viral diseases |
| EP3046924A1 (en) | 2013-09-20 | 2016-07-27 | IDENIX Pharmaceuticals, Inc. | Hepatitis c virus inhibitors |
| EP3063140A4 (en) | 2013-10-30 | 2017-11-08 | Merck Sharp & Dohme Corp. | Pseudopolymorphs of an hcv ns5a inhibitor and uses thereof |
| WO2015134561A1 (en) | 2014-03-05 | 2015-09-11 | Idenix Pharmaceuticals, Inc. | Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection |
| US20170066779A1 (en) | 2014-03-05 | 2017-03-09 | Idenix Pharmaceuticals Llc | Solid forms of a flaviviridae virus inhibitor compound and salts thereof |
| CN104292130B (zh) * | 2014-10-13 | 2016-04-27 | 苏州永健生物医药有限公司 | 一种波普瑞韦中间体2-羟基-3-氨基-4-环丁基丁酰胺盐酸盐的合成方法 |
| US11351149B2 (en) | 2020-09-03 | 2022-06-07 | Pfizer Inc. | Nitrile-containing antiviral compounds |
| JP2024529062A (ja) * | 2021-08-02 | 2024-08-01 | 北京華益健康薬物研究中心 | コロナウイルス感染症の治療又は予防のための３ｃｌプロテア－ゼ小分子阻害剤及びその用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4506666A (en) * | 1982-12-03 | 1985-03-26 | Kircaldie, Randall And Mcnab | Method and apparatus for rectifying obstructive apnea |
| ES2341534T3 (es) * | 2000-07-21 | 2010-06-22 | Schering Corporation | Peptidos como inhibidores de la serina proteasa ns3 del virus de la hepatitis c. |
| US7244721B2 (en) * | 2000-07-21 | 2007-07-17 | Schering Corporation | Peptides as NS3-serine protease inhibitors of hepatitis C virus |
| SV2003000617A (es) * | 2000-08-31 | 2003-01-13 | Lilly Co Eli | Inhibidores de la proteasa peptidomimetica ref. x-14912m |
| US7241796B2 (en) * | 2001-10-24 | 2007-07-10 | Vertex Pharmaceuticals Inc. | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
| KR20040077767A (ko) * | 2002-01-23 | 2004-09-06 | 쉐링 코포레이션 | Ｃ형 간염 바이러스 감염 치료용 ｎｓ3-세린 프로테아제억제제로서의 프롤린 화합물 |
| CA2370396A1 (en) * | 2002-02-01 | 2003-08-01 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis c inhibitor tri-peptides |
| JP2005173784A (ja) * | 2003-12-09 | 2005-06-30 | Nec Corp | 映像情報配信システム及び方法と装置並びにプログラム |
| US7245891B2 (en) * | 2003-10-21 | 2007-07-17 | Kyocera Wireless Corp. | Wireless mobile communication device having a speaker vibration alert and method of using same |
| ES2328589T3 (es) * | 2004-02-27 | 2009-11-16 | Schering Corporation | Compuestos de la prolina 3,4(ciclopentil) fusionados como inhibidores de la proteasa serina ns3 del virus de la hepatitis c. |
| US7635694B2 (en) * | 2004-02-27 | 2009-12-22 | Schering Corporation | Cyclobutenedione-containing compounds as inhibitors of hepatitis C virus NS3 serine protease |
-
2005
- 2005-02-24 AT AT05723688T patent/ATE514691T1/de not_active IP Right Cessation
- 2005-02-24 EP EP05723688A patent/EP1730142B1/en not_active Expired - Lifetime
- 2005-02-24 CA CA2557304A patent/CA2557304C/en not_active Expired - Fee Related
- 2005-02-24 RU RU2006134000/04A patent/RU2006134000A/ru not_active Application Discontinuation
- 2005-02-24 WO PCT/US2005/005924 patent/WO2005085242A1/en not_active Ceased
- 2005-02-24 PE PE2005000218A patent/PE20050999A1/es not_active Application Discontinuation
- 2005-02-24 BR BRPI0508217-0A patent/BRPI0508217A/pt not_active IP Right Cessation
- 2005-02-24 KR KR1020067017349A patent/KR20070026394A/ko not_active Ceased
- 2005-02-24 JP JP2007500975A patent/JP4874227B2/ja not_active Expired - Fee Related
- 2005-02-24 TW TW094105517A patent/TW200529822A/zh unknown
- 2005-02-24 AU AU2005219824A patent/AU2005219824B2/en not_active Ceased
- 2005-02-24 US US11/065,647 patent/US7173057B2/en not_active Expired - Fee Related
- 2005-02-24 CN CNA2005800126969A patent/CN1946718A/zh active Pending
- 2005-02-25 AR ARP050100717A patent/AR048023A1/es not_active Application Discontinuation
-
2006
- 2006-08-22 IL IL177628A patent/IL177628A0/en unknown
- 2006-08-23 ZA ZA200607048A patent/ZA200607048B/xx unknown
- 2006-08-25 EC EC2006006792A patent/ECSP066792A/es unknown
- 2006-09-26 NO NO20064355A patent/NO20064355L/no not_active Application Discontinuation
- 2006-11-20 US US11/602,174 patent/US7619094B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP1730142A1 (en) | 2006-12-13 |
| US20050222047A1 (en) | 2005-10-06 |
| US7619094B2 (en) | 2009-11-17 |
| JP2007525518A (ja) | 2007-09-06 |
| TW200529822A (en) | 2005-09-16 |
| CN1946718A (zh) | 2007-04-11 |
| JP4874227B2 (ja) | 2012-02-15 |
| KR20070026394A (ko) | 2007-03-08 |
| ECSP066792A (es) | 2006-11-16 |
| EP1730142B1 (en) | 2011-06-29 |
| NO20064355L (no) | 2006-11-24 |
| PE20050999A1 (es) | 2005-12-01 |
| IL177628A0 (en) | 2006-12-31 |
| AU2005219824A1 (en) | 2005-09-15 |
| AR048023A1 (es) | 2006-03-22 |
| WO2005085242A1 (en) | 2005-09-15 |
| ATE514691T1 (de) | 2011-07-15 |
| US20070093430A1 (en) | 2007-04-26 |
| CA2557304A1 (en) | 2005-09-15 |
| ZA200607048B (en) | 2008-06-25 |
| BRPI0508217A (pt) | 2007-07-17 |
| CA2557304C (en) | 2013-08-06 |
| AU2005219824B2 (en) | 2007-11-29 |
| US7173057B2 (en) | 2007-02-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2006134000A (ru) | Новые кетоамиды с циклическим p4s, действующие как ингибиторы сериновой протеазы ns3 ируса гепатита с | |
| RU2006134002A (ru) | Новые соединения, действующие как ингибиторы сериновой протеазы ns3 вируса гепатита с | |
| RU2006134005A (ru) | Новые соединения, действующие как ингибиторы сериновой протеазы ns3 вируса гепатита с | |
| RU2006134003A (ru) | Серосодержащие соединения, действующие как ингибиторы сериновой протеазы ns3 вируса гепатита с | |
| RU2404189C9 (ru) | Новые пептиды как ингибиторы ns3-серинпротеазы вируса гепатита c | |
| RU2006124594A (ru) | Ингибиторы сериновой протеазы ns3/ns4а вируса гепатита с | |
| JP2007535496A5 (enExample) | ||
| JP2007525514A5 (enExample) | ||
| JP2007525518A5 (enExample) | ||
| JP2007525510A5 (enExample) | ||
| CA2410662A1 (en) | Novel peptides as ns3-serine protease inhibitors of hepatitis c virus | |
| JP2007525512A5 (enExample) | ||
| RU2003105217A (ru) | Новые пептиды, как ингибиторы ns3-серинпротеазы вируса гепатита с | |
| JP2008511633A5 (enExample) | ||
| RU2003105221A (ru) | Новые пептиды, как ингибиторы ns3-серинпротеазы вируса гепатита с | |
| JP2004513881A5 (enExample) | ||
| RU2002123350A (ru) | Дипептиднитрильные ингибиторы катепсина К | |
| RU2000102359A (ru) | Фармацевтическая композиция, обладающая улучшенным противораковым действием и/или сниженными побочными эффектами, содержащая противораковый агент и производное гидроксамовой кислоты | |
| JP2004504404A5 (enExample) | ||
| RU2002129564A (ru) | Макроциклические ингибиторы сериновой ns3-протеазы, включающие n-циклические р2 структурные элементы вируса гепатита с | |
| RU2002131163A (ru) | Макроциклические ингибиторы ns3-серинпротезы вируса гепатита с, содержащие алкил- и арилаланиновые p2 фрагменты | |
| RU2012144751A (ru) | Гетероциклические соединения, эффективные для ингибирования киназы | |
| RU2003101319A (ru) | Фармацевтическая композиция, обладающая улучшенным противоопухолевым действием и/или сниженными побочными эффектами, содержащая противоопухолевый агент и производное гидроксамовой кислоты | |
| CN111836814A (zh) | 稠环化合物、其制备方法及用途 | |
| EP2702054A2 (en) | Novel bisaminoquinoline compounds, pharmaceutical compositions prepared therefrom and their use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20101101 |